002287 Stock Overview
Tibet Cheezheng Tibetan Medicine Co., Ltd. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
Tibet Cheezheng Tibetan Medicine Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥22.73 |
| 52 Week High | CN¥25.26 |
| 52 Week Low | CN¥16.27 |
| Beta | 0.64 |
| 11 Month Change | -5.01% |
| 3 Month Change | 13.82% |
| 1 Year Change | -4.74% |
| 33 Year Change | -16.25% |
| 5 Year Change | 7.73% |
| Change since IPO | -34.54% |
Recent News & Updates
Recent updates
Shareholder Returns
| 002287 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -5.2% | -6.0% | -6.7% |
| 1Y | -4.7% | -7.9% | 1.9% |
Return vs Industry: 002287 matched the CN Pharmaceuticals industry which returned -5.3% over the past year.
Return vs Market: 002287 underperformed the CN Market which returned 4% over the past year.
Price Volatility
| 002287 volatility | |
|---|---|
| 002287 Average Weekly Movement | 6.0% |
| Pharmaceuticals Industry Average Movement | 7.2% |
| Market Average Movement | 8.2% |
| 10% most volatile stocks in CN Market | 12.5% |
| 10% least volatile stocks in CN Market | 5.5% |
Stable Share Price: 002287 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 002287's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 3,091 | Kailie Liu | www.cheezheng.com.cn |
Tibet Cheezheng Tibetan Medicine Co., Ltd. engages in the research, development, production, and sale of Tibetan medicines in China. It provides products in the areas of orthopedics, neurology, dermatology, gynecology, pediatrics, respiratory, gastroenterology, cardiovascular, and cerebrovascular sectors.
Tibet Cheezheng Tibetan Medicine Co., Ltd. Fundamentals Summary
| 002287 fundamental statistics | |
|---|---|
| Market cap | CN¥12.05b |
| Earnings (TTM) | CN¥594.07m |
| Revenue (TTM) | CN¥2.27b |
20.3x
P/E Ratio5.3x
P/S RatioIs 002287 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 002287 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.27b |
| Cost of Revenue | CN¥400.73m |
| Gross Profit | CN¥1.87b |
| Other Expenses | CN¥1.28b |
| Earnings | CN¥594.07m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.12 |
| Gross Margin | 82.35% |
| Net Profit Margin | 26.16% |
| Debt/Equity Ratio | 47.3% |
How did 002287 perform over the long term?
See historical performance and comparison